Get started
Author

Allysha Bissessur

Institution: Zymeworks (Canada)
Observed institution: Zymeworks (Canada)
ORCID: 0009-0007-7597-3500
Observed ORCID: 0009-0007-7597-3500
OpenAlex ID: A5092122798
Abstract 2658: ZW251, a novel glypican-3-targeting antibody drug conjugate bearing a topoisomerase 1 inhibitor payload
2023 · Laurence Madera, Andrea Hernández Rojas, et al. · Cancer Research · 6
ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026 · Samuel Lawn, Andrea Hernandez Rojas, et al. · Clinical Cancer Research · 1
Supplementary Figure S1 from ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026 · Samuel Lawn, Andrea Hernandez Rojas, et al.
Supplementary Figure S3 from ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026 · Samuel Lawn, Andrea Hernandez Rojas, et al.
Data from ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026 · Samuel Lawn, Andrea Hernandez Rojas, et al.
Supplementary Figure S10 from ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026 · Samuel Lawn, Andrea Hernandez Rojas, et al.
Supplementary Figure S2 from ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026 · Samuel Lawn, Andrea Hernandez Rojas, et al.
Supplementary Figure S7 from ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026 · Samuel Lawn, Andrea Hernandez Rojas, et al.
Supplementary Figure S12 from ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026 · Samuel Lawn, Andrea Hernandez Rojas, et al.
Supplementary Figure S9 from ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026 · Samuel Lawn, Andrea Hernandez Rojas, et al.
Supplementary Table T3 from ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026 · Samuel Lawn, Andrea Hernandez Rojas, et al.
Supplementary Figure S6 from ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026 · Samuel Lawn, Andrea Hernandez Rojas, et al.
Supplementary Figure S13 from ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026 · Samuel Lawn, Andrea Hernandez Rojas, et al.
Supplementary Figure S4 from ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026 · Samuel Lawn, Andrea Hernandez Rojas, et al.
Supplementary Table T1 from ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026 · Samuel Lawn, Andrea Hernandez Rojas, et al.
Supplementary Table T2 from ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026 · Samuel Lawn, Andrea Hernandez Rojas, et al.
Supplementary Figure S8 from ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026 · Samuel Lawn, Andrea Hernandez Rojas, et al.
Supplementary Figure S11 from ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026 · Samuel Lawn, Andrea Hernandez Rojas, et al.
Supplementary Figure S5 from ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
2026 · Samuel Lawn, Andrea Hernandez Rojas, et al.
Abstract 2400: Design and evaluation of mRNA translation inhibitors for use as antibody drug conjugate payloads.
2026 · Mark Petersen, Jodi Wong, et al. · Cancer Research
Abstract 5640: ZW439, a novel CLDN18.2-targeting pan-RAS inhibitor antibody drug conjugate for the treatment of RAS mutated pancreatic cancer
2026 · Sam Lawn, Andrea Hernández Rojas, et al. · Cancer Research
Abstract 1686: Development of ZW418, a biparatopic PTK7-targeting antibody-drug conjugate incorporating a novel pan-RAS inhibitor payload for the treatment of non-small cell lung cancer
2026 · Luying Yang, Alex Wu, et al. · Cancer Research
Abstract 4431: ZW427, a Ly6E-targeting antibody drug conjugate bearing a novel pan-RAS inhibitor payload for the treatment of RAS mutated cancers
2026 · Dunja Urosev, Vidhi Khanna, et al. · Cancer Research
Abstract 3127: Development of three-dimensional cancer cell line spheroid models for the in vitro functional characterization of cytotoxic antibody-drug conjugates
2024 · Jodi Wong, Andrea Hernández Rojas, et al. · Cancer Research
Works count: 24
Citation count: 7
H-index: 1
I10-index:
Year
Topic
Type